Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Breast Cancer × Anastrozole × Clear all

Phase

Phase 3 4 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 85 Carcinoma, Intraductal, Noninfiltrating 6 Neoplasm Metastasis 3 Breast Neoplasms, Male 3 Breast Carcinoma In Situ 3 Triple Negative Breast Neoplasms 2 Neoplasms 2 Endometrial Neoplasms 2 Breast Cancer Metastatic 2 Sexual Dysfunction, Physiological 1 Seizures 1 Ovarian Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Locoregional Recurrence 1 Lethal Congenital Contracture Syndrome 2 1 Inflammatory Breast Neoplasms 1 Hypogonadism 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 HER2-positive Breast Cancer 1 HER2 Negative Breast Cancer 1 Fallopian Tube Neoplasms 1 Erectile Dysfunction 1 Epilepsy 1 ER+ Breast Cancer 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasm Female 1 Breast Diseases 1 Anatomic Stage III Breast Cancer AJCC v8 1 Advanced Breast Carcinoma 1 Advanced Breast Cancer 1

Interventions

Fulvestrant 7 olaparib 4 Capecitabine 4 pyrotinib 3 Docetaxel 3 Vinorelbine 2 Trastuzumab 2 Alpelisib 2 vandetanib 1 trastuzumab deruxtecan 1 talazoparib 1 sacituzumab govitecan 1 neratinib 1 liposomal doxorubicin 1 exemestane 1 eribulin 1 dalpiciclib 1 ceralasertib 1 cediranib 1 capivasertib 1 abemaciclib 1 Tablets 1 Moxifloxacin 1 Letrozole 1 Goserelin 1 Everolimus 1 Dasatinib 1 Cyclophosphamide 1 Cisplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04714619 2023-12-19

CAILA

MedSIR

Phase 2 Terminated

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡